Visiongain has launched a new pharma report Global Acute Myeloid Leukaemia Market Report: Chemotherapy, Targeted Therapy, Cytarabine, Daunorubicin, Midostaurin, Enasidenib.

The global acute myeloid leukaemia market is estimated to grow at a CAGR of 13% in the first half of the forecast period. In 2018, the chemotherapy segment held 32% share of the global acute myeloid leukaemia market.

The lead analyst of the report commented "The growth of the acute myeloid leukemia market is estimated to be catalysed by opportunities in emerging markets with high potential due to improving healthcare infrastructure, unmet healthcare needs, rise in chronic diseases, and increased awareness.

The healthcare industry in the emerging nations is developing at a significant rate due to rise in demand for better healthcare services, significant investments by government to improve healthcare infrastructure, and an increase in the incidence of acute myeloid leukemia."

Leading companies featured in the report include Bristol-Myers Squibb Company, Celgene, Clavis Pharma ASA, Daiichi Sankyo, Eisai, GSK, Novartis, Roche, Sunesis Pharmaceuticals Teva and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.